B. Riley analyst Kalpit Patel raised the firm’s price target on Journey Medical to $8 from $6 and keeps a Buy rating on the shares. Journey Medical announced that the FDA agreed that the proposed data package for DFD-29 was sufficient to support the NDA submission following a pre-NDA meeting, the analyst tells investors in a research note. The firm has increased conviction in the the drug’s erythema benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DERM:
- Journey Medical announces completion of pre-NDA meeting with FDA for DFD-29
- Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
- Biotech Alert: Searches spiking for these stocks today
- Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023